PLx Pharma Winddown Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Pat Lonergan

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.8yrs

Jüngste Management Updates

Recent updates

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

Aug 12

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

May 10

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

Nov 03

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

Sep 23

Geschäftsführer

Pat Lonergan (88 yo)

no data

Amtszeit

Mr. Patrick M. Lonergan, also known as Pat, co-founded Numark Laboratories Inc. in 1987 and has been its President since January 1989. Mr. Lonergan serves as Member of Chief Executive Officer Advisory Grou...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michael Valentino	Chairman	12.3yrs	US$393.75k	1.62% $ 0.5
Kirk Calhoun	Independent Director	8yrs	US$55.00k	0.0055% $ 0.002
Todd Rosengart	Member of Scientific Advisory Board	5.8yrs	keine Daten	keine Daten
Robert Casale	Independent Director	7.7yrs	US$75.50k	0.0089% $ 0.003
Gary Balkema	Independent Director	7.7yrs	US$50.00k	0.018% $ 0.005
P. Steg	Member of Scientific Advisory Board	5.8yrs	keine Daten	keine Daten
Deepak Bhatt	Member of Scientific Advisory Board	5.8yrs	keine Daten	keine Daten
Byron Cryer	Member of Scientific Advisory Board	5.8yrs	keine Daten	keine Daten
Jayne Prats	Member of Scientific Advisory Board	5.8yrs	keine Daten	keine Daten
Efthymios Deliargyris	Member of Scientific Advisory Board	3.5yrs	US$801.65k	keine Daten
Dominick Angiolillo	Member of Scientific Advisory Board	5.8yrs	keine Daten	keine Daten
Carey Kimmelstiel	Member of Scientific Advisory Board	5.8yrs	keine Daten	keine Daten

5.8yrs

Durchschnittliche Betriebszugehörigkeit

66.5yo

Durchschnittliches Alter

Erfahrener Vorstand: PLXP.QDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).

PLx Pharma Winddown Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Plx Pharma Winddown Corp. Announces Executive Changes

PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board

PLx Pharma Inc., Annual General Meeting, Nov 08, 2022

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

Recent updates

PLx Pharma Winddown Corp. Files Form 15

Plx Pharma Winddown Corp. Announces Executive Changes

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC

PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board

PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

PLx Pharma Inc., Annual General Meeting, Nov 08, 2022

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022

Consensus forecasts updated

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$16.33

PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

No longer forecast to breakeven

PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

PLx Pharma: First Commercial Launch Makes It Attractive

Consensus forecasts updated

PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month

Consensus revenue estimates fall to US$5.73m

Price target increased to US$21.50

PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August

Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in August

Executive Chairman recently bought US$100k worth of stock

PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Consensus forecasts updated

Consensus revenue estimates increase to US$6.80m

Earnings beat expectations

Executive Chairman recently bought US$200k worth of stock

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.

Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.

PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 Mg

New 90-day high: US$6.89

New 90-day high: US$6.50

PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration

PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma EPS misses by $0.10

Earnings miss expectations

New 90-day high: US$4.31

PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020

New 90-day high - US$4.18

PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020

PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index

Geschäftsführer

Amtszeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter